Phase 1 Clinical Trials with Oncology Radiopharmaceuticals: Safety Review Committee Conduct

Time: 1:30 pm
day: Day One

Details:

  • Ideal study designs: including 3+3 versus BOIN versus BOIN- TITE designs
  • Critical materials, AEs, SAEs, labs, AESI, dosimetry, pharmacokinetics
  • Facilitating expedited reviews for dose escalation/ de-escalation decisions

Speakers: